ABNewswire - Press Release Distribution Service

Thursday, June 1, 2023

Alpha-1 Antitrypsin Deficiency Pipeline | Companies - Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada, Ltd

DelveInsight’s, “Alpha1-Antitrypsin Deficiency Pipeline Insight 2023” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Alpha1-Antitrypsin Deficiency pipeline landscape. It covers the Alpha1-Antitrypsin Deficiency pipeline drug profiles, including Alpha1-Antitrypsin Deficiency clinical trials and nonclinical stage products. It also covers the Alpha1-Antitrypsin Deficiency therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Alpha-1 Antitrypsin Deficiency Pipeline treatment landscape of the report, click here @ Alpha-1 Antitrypsin Deficiency Pipeline Outlook

Key Takeaways from the Alpha-1 Antitrypsin Deficiency Pipeline Report

DelveInsight’s Alpha-1 Antitrypsin Deficiency Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Alpha-1 Antitrypsin Deficiency.
The leading Alpha-1 Antitrypsin Deficiency Companies include Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada, Ltd, and Others.
Promising Alpha-1 Antitrypsin Deficiency Pipeline Therapies include Fazirsiran Injection, Alpha-1 MP, ARO AAT, ALN-AAT02, and others
In March 2023, Takeda initiated a randomized, double-blind, placebo-controlled, Phase III study to evaluate theefficacy and safety of Fazirsiran in the treatment of Alpha-1 Antitrypsin Deficiency-Associated liver disease with METAVIR StageF2 to F4 fibrosis. The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Otheraims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects thebody (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT proteinin the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran workscompared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in theblood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well asto check for side effects in participants treated with fazirsiran compared with those who received placebo. The trial is currentlyrecruiting participants and is expected to be completed by March 2027, with an estimated enrollment of 160 participants.

For further information, refer to the detailed Alpha-1 Antitrypsin Deficiency Unmet Needs, Alpha-1 Antitrypsin Deficiency Market Drivers, and Alpha-1 Antitrypsin Deficiency Market Barriers, click here for Alpha-1 Antitrypsin Deficiency Ongoing Clinical Trial Analysis

Alpha-1 Antitrypsin Deficiency Overview

Alpha-1-antitrypsin (AAT) is a protein produced in the liver that protects the body's tissues from being damaged by infection-fighting agents released by its immune system. In alpha-1 antitrypsin deficiency, the body’s normal production of AAT is reduced, resulting in the destruction of sensitive lung tissue. AAT deficiency is inherited. The severity of disease depends in part on the abnormalities present in the genes inherited from each parent. It is estimated that there are between 80,000 to 100,000 individuals affected by AAT deficiency in the United States.

Alpha-1 Antitrypsin Deficiency Emerging Drugs Profile

ARO AAT: Arrowhead Pharmaceuticals

ARO AAT is a second generation, N-Acetylgalactosamine (GalNAc) based, subcutaneously administered RNA interference based therapeutic. ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. In June 2019, the US FDA has granted Fast Track designation to ARO-AAT. ARO-AAT is in Phase III clinical studies for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD).

ALN-AAT02: Alnylam Pharmaceuticals

ALN AAT02 is a subcutaneously administered RNAi therapeutic that targets alpha-1 antitrypsin (AAT). ALN-AAT02 is based on the Alnylam's enhanced stabilization chemistry plus (ESC+)-GalNAc-conjugate technology, which enables subsequent subcutaneous dosing with increased selectivity and a wide therapeutic index. The drug is currently in Phase I/II clinical development for the treatment of ZZ Type AAT Deficiency Liver Disease.

Request a sample and discover the recent advances in Alpha-1 Antitrypsin Deficiency Ongoing Clinical Trial Analysis and Medications, click here @ Alpha-1 Antitrypsin Deficiency Treatment Landscape

Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics Assessment

There are approx. 12+ key companies which are developing the therapies for Alpha-1 Antitrypsin Deficiency. The companies which have their Alpha-1 Antitrypsin Deficiency drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

Dive deep into rich insights for drugs for Alpha-1 Antitrypsin Deficiency Market Drivers and Alpha-1 Antitrypsin Deficiency Market Barriers, click here @ Alpha-1 Antitrypsin Deficiency Unmet Needs and Analyst Views

Scope of the Alpha-1 Antitrypsin Deficiency Pipeline Report

Coverage- Global
Alpha-1 Antitrypsin Deficiency Companies- Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada, Ltd, and Others.
Alpha-1 Antitrypsin Deficiency Pipeline Therapies- Fazirsiran Injection, Alpha-1 MP, ARO AAT, ALN-AAT02, and others
Alpha-1 Antitrypsin Deficiency Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Alpha-1 Antitrypsin Deficiency Mergers and acquisitions, Alpha-1 Antitrypsin Deficiency Licensing Activities @ Alpha-1 Antitrypsin Deficiency Emerging Drugs, and Recent Trends

Table of Content

Introduction
Executive Summary
Alpha-1 Antitrypsin Deficiency: Overview
Pipeline Therapeutics
Therapeutic Assessment
Alpha-1 Antitrypsin Deficiency– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ARO AAT: Arrowhead Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
ALN-AAT02: Alnylam Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Alpha-1 Antitrypsin Deficiency Key Companies
Alpha-1 Antitrypsin Deficiency Key Products
Alpha-1 Antitrypsin Deficiency- Unmet Needs
Alpha-1 Antitrypsin Deficiency- Market Drivers and Barriers
Alpha-1 Antitrypsin Deficiency- Future Perspectives and Conclusion
Alpha-1 Antitrypsin Deficiency Analyst Views
Alpha-1 Antitrypsin Deficiency Key Companies
Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Cytomegalovirus Infection Market expected to rise, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines

Cytomegalovirus Infection Market

DelveInsight's "Cytomegalovirus (CMV) Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cytomegalovirus (CMV) Infection, historical and forecasted epidemiology as well as the Cytomegalovirus (CMV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Cytomegalovirus Infection market growth is driven by factors like increase in the prevalence of Cytomegalovirus Infection, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Cytomegalovirus Infection market report also offers comprehensive insights into the Cytomegalovirus Infection market size, share, Cytomegalovirus Infection epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Cytomegalovirus Infection market size growth forward.

Some of the key highlights from the Cytomegalovirus Infection Market Insights Report:

Several key pharmaceutical companies, including Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook.
Promising Cytomegalovirus Infection pipeline therapies in various stages of development include mRNA-1647, and others.
The total Cytomegalovirus Infection market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major market.
As per DelveInsight analysis, the Cytomegalovirus Infection market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Cytomegalovirus Infection Market Landscape

Cytomegalovirus Infection Overview

Cytomegalovirus (CMV) is a wide-spread virus, with manifestations ranging from asymptomatic to severe end-organ dysfunction in immunocompromised patients with congenital CMV disease. Human cytomegalovirus is a member of the viral family known as herpesviruses, Herpesviridae, or human herpesvirus-5 (HHV-5). Human cytomegalovirus infections commonly are associated with the salivary glands. CMV infection may be asymptomatic in healthy people, but they can be life-threatening in an immunocompromised patient.

Do you know the treatment paradigms for different countries? Download our Cytomegalovirus Infection Market Sample Report

Cytomegalovirus Infection Epidemiology Segmentation

DelveInsight’s Cytomegalovirus Infection market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Cytomegalovirus Infection historical patient pools and forecasted Cytomegalovirus Infection patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Cytomegalovirus Infection Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

Cytomegalovirus Infection Prevalence
Age-Specific Cytomegalovirus Infection Prevalence
Gender-Specific Cytomegalovirus Infection Prevalence
Diagnosed and Treatable Cases of Cytomegalovirus Infection

Visit for more @ Cytomegalovirus Infection Epidemiological Insights

Cytomegalovirus Infection Treatment Market

The Cytomegalovirus Infection market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cytomegalovirus Infection market trends by analyzing the impact of current Cytomegalovirus Infection therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Cytomegalovirus Infection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cytomegalovirus Infection market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cytomegalovirus Infection market in 7MM is expected to witness a major change in the study period 2019-2032.

Cytomegalovirus Infection Key Companies

Moderna

Cytomegalovirus Infection Pipeline Therapies

mRNA-1647

Cytomegalovirus Infection Pipeline Analysis: Drug Profile

mRNA-1647: Moderna

mRNA-1647 includes six mRNAs encoding two antigens in one vaccine and is developed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex, and one mRNA encodes the glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is vital for CMV entry into a majority of cells, including epithelial cells, while gB is essential for entry into all susceptible cells, including fibroblasts. A vaccine that develops an immune response against both pentamer and gB has the potential to prohibit CMV entry into a range of target cell types and thus inhibit primary and congenital infections.

For more information, visit Cytomegalovirus Infection Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Cytomegalovirus Infection Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Cytomegalovirus Infection, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Cytomegalovirus Infection epidemiology in the 7MM
Cytomegalovirus Infection marketed and emerging therapies
Cytomegalovirus Infection companies
Cytomegalovirus Infection market drivers and barriers

Key Questions Answered in the Cytomegalovirus Infection Market Report 2032:

What was the Cytomegalovirus Infection market share distribution in 2019, and how would it appear in 2032?
What is the total Cytomegalovirus Infection market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Cytomegalovirus Infection market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Cytomegalovirus Infection market projected to expand at 7MM?

Table of Contents:

1 Cytomegalovirus Infection Market Key Comprehensive Insights

2 Cytomegalovirus Infection Market Report Introduction

3 Competitive Intelligence Analysis for Cytomegalovirus Infection

4 Cytomegalovirus Infection Market Analysis Overview at a Glance

5 Executive Summary of Cytomegalovirus Infection

6 Cytomegalovirus Infection Epidemiology and Market Methodology

7 Cytomegalovirus Infection Epidemiology and Patient Population

8 Cytomegalovirus Infection Patient Journey

9 Cytomegalovirus Infection Treatment Algorithm, Cytomegalovirus Infection Current Treatment, and Medical Practices

10 Key Endpoints in Cytomegalovirus Infection Clinical Trials

11 Cytomegalovirus Infection Marketed Therapies

12 Cytomegalovirus Infection Emerging Therapies

13 Cytomegalovirus Infection: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Cytomegalovirus Infection

16 Cytomegalovirus Infection Market Key Opinion Leaders Reviews

18 Cytomegalovirus Infection Market Drivers

19 Cytomegalovirus Infection Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Cytomegalovirus Infection Epidemiology 2032

DelveInsight's "Cytomegalovirus Infection - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Cytomegalovirus Infection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cytomegalovirus Infection Pipeline 2023

"Cytomegalovirus Infection Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cytomegalovirus Infection market. A detailed picture of the Cytomegalovirus Infection pipeline landscape is provided, which includes the disease overview and Cytomegalovirus Infection treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

CRISPR Therapies Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Intellia, CRISPR Therapeutics, Caribou, Emendo, Sarepta, Editas, AstraZeneca

DelveInsight Business Research LLP

As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the CRISPR therapeutics market. Several of the CRISPR therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“CRISPR Therapies Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the CRISPR Therapies Market.

The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

CRISPR Therapies Pipeline Analysis

CRISPR Therapies Pipeline Analysis

The report provides insights into:

The report provides detailed insights into emerging therapies in the CRISPR Market and the aggregate therapies developed by major pharma companies.
It accesses the different CRISPR therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the CRISPR Therapies Market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, featured press releases from company/university websites, industry-specific third-party sources, etc.

Learn How the Ongoing Clinical & Commercial Activities will Affect the CRISPR Therapies Therapeutic Segment @

https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight

Phases of Emerging Therapies

DelveInsight’s Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

CRISPR Therapies Therapeutics Landscape

There are approx. 25+ key companies which are developing CRISPR Therapies. Currently, CRISPR Therapeutics is leading the therapeutics market with its CRISPR Therapies drug candidates in the most advanced stage of clinical development.

Leading CRISPR Therapies Companies in the Therapeutics Market Include:

Intellia Therapeutics
CRISPR therapeutics
Repare Therapeutics
Beam therapeutics
Caribou Biosciences
Emendo Biotherapeutics
Defence Therapeutics
Sarepta therapeutics
Editas Medicine
Locus Biosciences
Excision BioTherapeutics
AstraZeneca
Novartis
ASC therapeutics
Casebia therapeutics
Spotlight Therapeutics
KSQ Therapeutics
MEDIC Life Sciences
Scribe therapeutics
Arbor Biotechnologies
Sangamo therapeutics
Graphite Bio
Nuntius Therapeutics

And Many Others

CRISPR Therapies Emerging and Marketed Drugs Covered in the Report Include:

CTX001: CRISPR Therapeutics
EDIT-101: Editas Medicine

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. CRISPR Therapies Current Treatment Patterns

4. CRISPR Therapies - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. CRISPR Therapies Late Stage Products (Phase-III)

7. CRISPR Therapies Mid-Stage Products (Phase-II)

8. CRISPR Therapies Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. CRISPR Therapies Discontinued Products

13. CRISPR Therapies Product Profiles

14. CRISPR Therapies Companies in the Market

15. Key Products in the CRISPR Therapies Therapeutics Segment

16. Dormant and Discontinued Products

17. CRISPR Therapies Unmet Needs

18. CRISPR Therapies Future Perspectives

19. CRISPR Therapies Analyst Review

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Traveler's Diarrhea Market

"Traveler's Diarrhea Market Insights, Epidemiology, and Market Forecast-2032" report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Traveler's Diarrhea market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Traveler's Diarrhea market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Crohn's Disease Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Janssen, RedHill Biopharma, Gilead, Galapagos, Eilly Lilly, Takeda

Delveinsight Business Research LLP

As per DelveInsight's assessment, globally, about 90+ key pharma and biotech companies are working on 90+ pipeline drugs in the Crohn's Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Crohn's Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Crohn's Disease Market.

The Crohn's Disease Pipeline report embraces in-depth commercial, regulatory, and Crohn's Disease clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Crohn's Disease drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Crohn's Disease Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the emerging therapies for Crohn's Disease treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Crohn's Disease therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Crohn's Disease companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Crohn's Disease drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Crohn's Disease therapeutic market.

Crohn's Disease Pipeline Analysis

Analysis of Emerging Crohn's Disease Therapies by Phases

The report covers the emerging products under different phases of clinical development like -

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Intramuscular
Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Learn How the Crohn's Disease Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/crohns-disease-pipeline-insight

Crohn's Disease Therapeutics Landscape

There are approx. 90+ key companies developing therapies for Crohn’s Disease. Currently, Janseen is leading the therapeutics market with its Crohn’s Disease drug candidates in the most advanced stage of clinical development.

Crohn's Disease Companies Actively Working in the Therapeutic Market Include:

4D Pharma, Abbvie, Abivax, Aclaris Therapeutics, Active Biotech, Aibios Co Ltd, Akeso Biopharma, Alfasigma, Algernon Pharmaceuticals, Alpha Cancer Technologies, Amgen, Arena Pharmaceuticals, Artelo Biosciences, Assembly Biosciences, AstraZeneca, Athos Therapeutics, Atlantic Bio Sci, Atlantic Healthcare, Avexegen Therapeutics, Avobis Bio LLC, Bristol-Myers Squibb, Celgene, Celularity, Cerecor, ChemoCentryx, Chong Kun Dang Pharmaceutical Corp, Cloud Pharmaceuticals, Commence Bio Inc, Curacle, Cytocom, Denali Therapeutics, Draconis Pharma, Educell doo, Eisai, Eli Lilly and Company, Enzo Biochem Inc., Exeliom Biosciences SAS, Fast Forward Pharmaceuticals, Finch Therapeutics, Gilead Sciences, GlaxoSmithKline, HAV Vaccines Ltd, Hoffmann-La Roche, Iltoo Pharma, Immunic, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovimmune Biotherapeutics, Intract Pharma Ltd, Janssen, JHL Biotech, Kang Stem Biotech, Koutif Therapeutics, Landos Biopharma, MakScientific, Metacrine, Mitsubishi Tanabe Pharma Corporation, Morphic Therapeutic, Navidea Biopharmaceuticals, Neuclone, Orchard Therapeutics, Origo Biopharma, Pfizer, PlantPraxis, Priothera, Protagonist Therapeutics, Provention Bio, Qu Biologics, RedHill Biopharma, Reistone Biopharma Company Limited, Roche, SLA Pharma, Soligenix, Stero Biotechs, Suzhou Connect Biopharmaceuticals, Synedgen, Synlogic, TaiwanJ Pharmaceuticals, Takeda Pharmaceuticals, Temisis Therapeutics, Tetherex Pharmaceuticals, Theravance Biopharma, Thetis Pharmaceuticals, Tiziana Life Sciences, Tract Therapeutics, Trio medicines, VHsquared Ltd., Winston Pharmaceuticals, Xbrane, and others.

Emerging and Marketed Crohn's Disease Drugs Covered in the Report Include:

Guselkumab: Janssen
RHB-104: RedHill Biopharma
Jyselica (Filgotinib): Gilead Sciences/ Galapagos NV
Mirikizumab (LY3074828): Eilly Lilly and Company
Entyvio (Vedolozumab): Takeda Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Crohn's Disease Companies Working in the Market @

https://www.delveinsight.com/sample-request/crohns-disease-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Crohn's Disease Treatment Patterns

4. Crohn's Disease - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Crohn's Disease Late Stage Products (Phase-III)

7. Crohn's Disease Mid-Stage Products (Phase-II)

8. Crohn's Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Crohn's Disease Discontinued Products

13. Crohn's Disease Product Profiles

14. Major Crohn's Disease Companies in the Market

15. Key Products in the Crohn's Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Crohn's Disease Unmet Needs

18. Crohn's Disease Future Perspectives

19. Crohn's Disease Analyst Review

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/crohns-disease-pipeline-insight

About DelveInsight

Other Trending Healthcare Reports By DelveInsight

Helicobacter Pylori Infections Market

"Helicobacter Pylori Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Helicobacter Pylori Infections market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Helicobacter Pylori Infections market.

Complicated Intra-Abdominal Infections Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MerLion, AiCuris, Novartis, Allecra, AbbVie, Shionogi

Delveinsight Business Research LLP

As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Complicated Intra-Abdominal Infections therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Complicated Intra-Abdominal Infections Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Complicated Intra-Abdominal Infections Market.

The Complicated Intra-Abdominal Infections Pipeline report embraces in-depth commercial, regulatory, and Complicated Intra-Abdominal Infections clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Complicated Intra-Abdominal Infections drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Complicated Intra-Abdominal Infections Pipeline Analysis

Complicated Intra-Abdominal Infections Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the emerging therapies for Complicated Intra-Abdominal Infections treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Complicated Intra-Abdominal Infections therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Complicated Intra-Abdominal Infections companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Complicated Intra-Abdominal Infections drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Complicated Intra-Abdominal Infections therapeutic market.

Analysis of Emerging Complicated Intra-Abdominal Infections Therapies by Phases

The report covers the emerging products under different phases of clinical development like -

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration

Complicated Intra-Abdominal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
intravitreal
Subretinal
Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Learn How the Complicated Intra-Abdominal Infections Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/complicated-intra-abdominal-infections-pipeline-insight

Complicated Intra-Abdominal Infections Therapeutics Landscape

There are approx. 15+ key companies developing therapies for Complicated Intra-Abdominal Infections. Currently, AbbVie is leading the therapeutics market with its Complicated Intra-Abdominal Infections drug candidates in the most advanced stage of clinical development.

Complicated Intra-Abdominal Infections Companies Actively Working in the Therapeutic Market Include:

MerLion Pharmaceuticals
AiCuris
Novartis
Allecra
AbbVie
AstraZeneca
Pfizer
Shionogi
Iterum Therapeutics
Nosopharm

And Many Others

Emerging and Marketed Complicated Intra-Abdominal Infections Drugs Covered in the Report Include:

Sulopenem: Interim Therapeutics
Avibactam/aztreonam: AbbVie

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Complicated Intra-Abdominal Infections Companies Working in the Market @

https://www.delveinsight.com/sample-request/complicated-intra-abdominal-infections-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Complicated Intra-Abdominal Infections Treatment Patterns

4. Complicated Intra-Abdominal Infections - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Complicated Intra-Abdominal Infections Late Stage Products (Phase-III)

7. Complicated Intra-Abdominal Infections Mid-Stage Products (Phase-II)

8. Complicated Intra-Abdominal Infections Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Complicated Intra-Abdominal Infections Discontinued Products

13. Complicated Intra-Abdominal Infections Product Profiles

14. Major Complicated Intra-Abdominal Infections Companies in the Market

15. Key Products in the Complicated Intra-Abdominal Infections Therapeutics Segment

16. Dormant and Discontinued Products

17. Complicated Intra-Abdominal Infections Unmet Needs

18. Complicated Intra-Abdominal Infections Future Perspectives

19. Complicated Intra-Abdominal Infections Analyst Review

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/complicated-intra-abdominal-infections-pipeline-insight

About DelveInsight

Other Trending Healthcare Reports By DelveInsight

Cushing's Syndrome Market

"Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Cushing's Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Cushing's Syndrome market.

Short Bowel Syndrome Pipeline | Companies - VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and Others

DelveInsight’s, “Short Bowel Syndrome Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Short Bowel Syndrome pipeline landscape. It covers the Short Bowel Syndrome pipeline drug profiles, including Short Bowel Syndrome clinical trials and nonclinical stage products. It also covers the Short Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Short Bowel Syndrome Pipeline treatment landscape of the report, click here @ Short Bowel Syndrome Pipeline Outlook

Key Takeaways from the Short Bowel Syndrome Pipeline Report

DelveInsight’s Short Bowel Syndrome Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Short Bowel Syndrome.
The leading Short Bowel Syndrome Companies include VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and Others
Promising Short Bowel Syndrome Pipeline Therapies include Teduglutide, Apraglutide, Glepaglutide, and others
Glepaglutide is developed by Zealand Pharma, which is under Phase III stage of clinical development for the treatment of patients with SBS. The drug received orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of SBS in October 2017. Glepaglutide is a long-acting GLP-2 analog with an effective half-life of ~50 h. The drug is given as once- or twice-weekly dosing via autoinjector. Moreover, the Phase II results showed an increase in intestinal absorption following 3 week administration. The Phase III program will provide up to 4.5 years patient exposure to glepaglutide and clinical evidence for efficacy and safety. The company announced completion of patient enrollment in the pivotal Phase III trial (EASE-SBS 1) of glepaglutide. Furthermore, the full results of the EASE-SBS 1 pivotal Phase III trial are expected in the third quarter of 2022.
In Feb2022, the company announced that the first patient has been dosed in its pivotal Phase III (STARS) trial of Apraglutide in SBS.The pivotal study is expected to be completed by June 2023 and the topline results are expected by end of 2023. The FDAhas granted Orphan Drug designation to Apraglutide an investigational treatment for SBS. Apraglutide is the lead candidate of the VectivBioand the companycompleted the Phase II clinical trial. Apraglutide has successfully completed Phase II studies and is currently being evaluatedin a pivotal Phase III clinical trial. In Phase II, the drug showed an Increase in intestinal absorption after weekly dosing.
In April 2021, 9 Meters Biopharma entered into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).

For further information, refer to the detailed Short Bowel Syndrome Unmet Needs, Short Bowel Syndrome Market Drivers, and Short Bowel Syndrome Market Barriers, click here for Short Bowel Syndrome Ongoing Clinical Trial Analysis

Short Bowel Syndrome Overview

Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm) leading to the need for nutritional and fluid supplements. Short bowel syndrome may be classified as a cause or subcategory of intestinal failure.

Short Bowel Syndrome Emerging Drugs Profile

Glepaglutide: Zealand Pharma

Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome.

Request a sample and discover the recent advances in Short Bowel Syndrome Ongoing Clinical Trial Analysis and Medications, click here @ Short Bowel Syndrome Treatment Landscape

Short Bowel Syndrome Pipeline Therapeutics Assessment

There are approx. 18+ Short Bowel Syndrome companies are developing Short Bowel Syndrome therapies. The Short Bowel Syndrome companies which have their Short Bowel Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zealand Pharma.

Dive deep into rich insights for drugs for Short Bowel Syndrome Market Drivers and Short Bowel Syndrome Market Barriers, click here @ Short Bowel Syndrome Unmet Needs and Analyst Views

Scope of the Short Bowel Syndrome Pipeline Report

Coverage- Global
Short Bowel Syndrome Companies- VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and Others
Short Bowel Syndrome Pipeline Therapies- Teduglutide, Apraglutide, Glepaglutide, and others.
Short Bowel Syndrome Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Short Bowel Syndrome Mergers and acquisitions, Short Bowel Syndrome Licensing Activities @ Short Bowel Syndrome Emerging Drugs, and Recent Trends

Table of Content

Introduction
Executive Summary
Short Bowel Syndrome: Overview
Pipeline Therapeutics
Therapeutic Assessment
Short Bowel Syndrome – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Glepaglutide: Zealand Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
HM 15912: Hanmi Pharmaceutical
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Vurolenatide: 9 Meters Biopharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SEFA-6179: NorthSea Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
GLP2-ELP: PhaseBio Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Short Bowel Syndrome Key Companies
Short Bowel Syndrome Key Products
Short Bowel Syndrome- Unmet Needs
Short Bowel Syndrome- Market Drivers and Barriers
Short Bowel Syndrome- Future Perspectives and Conclusion
Short Bowel Syndrome Analyst Views
Short Bowel Syndrome Key Companies
Appendix

About Us

Uterine Leiomyosarcoma Pipeline | Companies - Novartis, PharmMar, and Others

DelveInsight’s, “Uterine Leiomyosarcoma Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Uterine Leiomyosarcoma pipeline landscape. It covers the Uterine Leiomyosarcoma pipeline drug profiles, including Uterine Leiomyosarcoma clinical trials and nonclinical stage products. It also covers the Uterine Leiomyosarcoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Uterine Leiomyosarcoma Pipeline treatment landscape of the report, click here @ Uterine Leiomyosarcoma Pipeline Outlook

Key Takeaways from the Uterine Leiomyosarcoma Pipeline Report

DelveInsight’s Uterine Leiomyosarcoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Uterine Leiomyosarcoma.
The leading Uterine Leiomyosarcoma Companies include Novartis, PharmMar, and Others
Promising Uterine Leiomyosarcoma Pipeline Therapies include Trabectedin, Letrozole, and others.
The primary form of treatment for a Uterine Leiomyosarcoma is surgical removal of the entire tumor and any affected tissue. Total surgical removal of the uterus (hysterectomy) is usually performed. Anti-cancer drugs used alone or combination (chemotherapy) and radiation therapy have been used to treat individuals with leiomyosarcoma following surgery (adjuvant therapy) with limited benefit. Leiomyosarcomas have a high risk of recurrence, individuals should be examined routinely after surgery.
The Uterine Leiomyosarcoma companies and academics are working to assess challenges and seek opportunities that could influence Uterine Leiomyosarcoma R&D. The Uterine Leiomyosarcoma therapies under development are focused on novel approaches to treat/improve Uterine Leiomyosarcoma.

For further information, refer to the detailed Uterine Leiomyosarcoma Unmet Needs, Uterine Leiomyosarcoma Market Drivers, and Uterine Leiomyosarcoma Market Barriers, click here for Uterine Leiomyosarcoma Ongoing Clinical Trial Analysis

Uterine Leiomyosarcoma Overview

A Uterine Leiomyosarcoma (ULMS) is a rare malignant (cancerous) tumor that arises from the smooth muscle lining the walls of the uterus (myometrium). Leiomyosarcoma is classified as a soft tissue sarcoma. Sarcomas are malignant tumors that arise from the connective tissue, which connects, supports and surrounds various structures and organs in the body. Soft tissue includes fat, muscle, never, tendons, tissue surrounding the joints (synovial tissue), and blood and lymph vessels. The exact cause of leiomyosarcoma, including Uterine Leiomyosarcoma, is unknown.

Uterine Leiomyosarcoma Emerging Drugs Profile

Trabectedin: PharmMar

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

Letrozole: Novartis

Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormone.8 In postmenopausal women, the action of aromatase is responsible for the majority of estrogen production. With reduced availability of estrogen, estrogen-dependant tumors regress. Third generation aromatase inhibitors do not significantly affect cortisol, aldosterone, and thyroxine levels. Currently, in phase II of clinical trials.

Request a sample and discover the recent advances in Uterine Leiomyosarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Uterine Leiomyosarcoma Treatment Landscape

Uterine Leiomyosarcoma Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Uterine Leiomyosarcoma. The companies which have their Uterine Leiomyosarcoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Novartis and others.

Dive deep into rich insights for drugs for Uterine Leiomyosarcoma Market Drivers and Uterine Leiomyosarcoma Market Barriers, click here @ Uterine Leiomyosarcoma Unmet Needs and Analyst Views

Scope of the Uterine Leiomyosarcoma Pipeline Report

Coverage- Global
Uterine Leiomyosarcoma Companies- Novartis, PharmMar, and Others
Uterine Leiomyosarcoma Pipeline Therapies- Trabectedin, Letrozole, and others
Uterine Leiomyosarcoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Uterine Leiomyosarcoma Mergers and acquisitions, Uterine Leiomyosarcoma Licensing Activities @ Uterine Leiomyosarcoma Emerging Drugs, and Recent Trends

Table of Content

Introduction
Executive Summary
Uterine Leiomyosarcoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Uterine Leiomyosarcoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Uterine Leiomyosarcoma Collaboration Deals
Late Stage Products (Phase III)
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Letrozole: Novartis
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
Uterine Leiomyosarcoma Key Companies
Uterine Leiomyosarcoma Key Products
Uterine Leiomyosarcoma- Unmet Needs
Uterine Leiomyosarcoma- Market Drivers and Barriers
Uterine Leiomyosarcoma- Future Perspectives and Conclusion
Uterine Leiomyosarcoma Analyst Views
Uterine Leiomyosarcoma Key Companies
Appendix

About Us

Uveitis Pipeline | Companies - Eli Lilly and Company, Santen Inc, Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology

DelveInsight’s, “Uveitis Pipeline Insight 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Uveitis pipeline landscape. It covers the Uveitis pipeline drug profiles, including Uveitis clinical trials and nonclinical stage products. It also covers the Uveitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Uveitis Pipeline treatment landscape of the report, click here @ Uveitis Pipeline Outlook

Key Takeaways from the Uveitis Pipeline Report

DelveInsight’s Uveitis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Uveitis.
The leading Uveitis Companies include Eli Lilly and Company, Santen Inc, Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and Others.
Promising Uveitis Pipeline Therapies include Barcitinib, EYS606, Adalimumab, Prednisone, Fluocinolone Acetonide Intravitreal Implant 0.18 mg, QLETLI, Prednisone, Dexamethasone, and others
RG6179 (RO720220) is a nonsteroidal drug to improve vision in people with uveitis macular edema. It is administered through the intravitreal route and is a potent blocker of free IL-6, and IL-6 complexed to the soluble IL-6 receptor (IL-6R). Currently, it is being investigated in two Phase III trials, and this study aims to assess the safety and efficacy of RO720220 in participants with uveitis macular edema.
Baricitinib (Eli Lilly and Company): It is a Janus kinase selective inhibitor that works by interfering with cytokine signaling to influence immune cell function and inflammation by reducing phosphorylation and activating signal transducers and activators of transcription. It is currently being developed in the Phase III trial initiated in patients with active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis.
OCS-02 (Oculis): OCS-02 is a single-chain antibody fragment that binds to and neutralizes the activity of human TNFα. Based on the dual mechanism of action, including anti-inflammatory and anti-necrosis properties, the company anticipated initiating Phase IIb clinical trials in the first half of 2023, evaluating its use as a potential treatment for noninfectious anterior uveitis.
Izokibep (Acelyrin/Affibody Medical): ABY-035 is a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies. It is being developed for treating posterior uveitis, pan uveitis, noninfectious uveitis, and intermediate uveitis. Izokibep can reach high drug exposure levels through a single SC injection due to its small molecular size. Currently, it is being investigated in Phase IIb for noninfectious uveitis.

For further information, refer to the detailed Uveitis Unmet Needs, Uveitis Market Drivers, and Uveitis Market Barriers, click here for Uveitis Ongoing Clinical Trial Analysis

Uveitis Overview

Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. These diseases can slightly reduce vision or lead to severe vision loss. Uveitis is swelling of the middle layer of the eye, which is called the uvea. It may occur from both infectious and non-infectious causes. Uveitis is caused by inflammatory responses inside the eye. Inflammation is the body’s natural response to tissue damage, germs, or toxins.

Uveitis Emerging Drugs

Barcitinib: Eli Lilly and Company

Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling. Eli Lilly and Company is conducting a Phase III clinical trial to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.

EYS606: Eyevensys

EYS606 is a novel non-viral gene therapy approach being developed for the treatment of chronic non-infectious uveitis (CNIU) is being evaluated in Phase II stage of development. EYS606 combines plasmids encoding a potent fusion protein that neutralizes the activity of TNF-α and the proprietary Eyevensys Electrotransfection System used to introduce the plasmids into the eye. TNF is a cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in CNIU. EYS606 has already received orphan designation in Europe and is being investigated in 2 ongoing clinical trials enrolling patients with CNIU.

Request a sample and discover the recent advances in Uveitis Ongoing Clinical Trial Analysis and Medications, click here @ Uveitis Treatment Landscape

Uveitis Pipeline Therapeutics Assessment

There are approx. 15+ key companies are developing therapies for Uveitis. The companies which have their Uveitis drug candidates in the most advanced stage, i.e. Phase III include Eli Lilly and Company.

Dive deep into rich insights for drugs for Uveitis Market Drivers and Uveitis Market Barriers, click here @ Uveitis Unmet Needs and Analyst Views

Scope of the Uveitis Pipeline Report

Coverage- Global
Uveitis Companies- Eli Lilly and Company, Santen Inc, Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and Others.
Uveitis Pipeline Therapies- Barcitinib, EYS606, Adalimumab, Prednisone, Fluocinolone Acetonide Intravitreal Implant 0.18 mg, QLETLI, Prednisone, Dexamethasone, and others.
Uveitis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Uveitis Mergers and acquisitions, Uveitis Licensing Activities @ Uveitis Emerging Drugs, and Recent Trends

Table of Content

Introduction
Executive Summary
Uveitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Baricitinib: Eli Lilly and Company
Drug profiles in the detailed report…..
Mid-Stage Products (Phase II)
EYS606: Eyevensys
Drug profiles in the detailed report…..
Early-stage products (Phase I/II)
TRS01: Tarius Pharma
Drug profiles in the detailed report…..
Inactive Products
Uveitis Key Companies
Uveitis Key Products
Uveitis- Unmet Needs
Uveitis- Market Drivers and Barriers
Uveitis- Future Perspectives and Conclusion
Uveitis Analyst Views
Uveitis Key Companies
Appendix

About Us

Christopher Linton Discusses How He Defines Success In Exclusive Industry Elites Interview

Houston, Texas - June 1, 2023 - Christopher Linton is the CEO and founder of Lonestar Labor Management, an industry-leading staffing agency committed to helping individuals locate long-term employment. By providing an extensive range of workforce solutions, their team of professionals help ensure the proper training, compensation, and benefits. By working predominantly in the food and manufacturing industries, Lonestar Labor Management has cultivated partnerships with many organizations to improve the value of the workforce across the United States.

Christopher recently sat down with the individuals at Industry Elites to discuss his journey to the top. Despite his ongoing success in business, Christopher claims that he encounters his fair share of challenges. When asked to discusses some of his most memorable experiences he states,

“Business is always trial and error and it was no different for our team and Lonestar. We work with organizations across the United States and we employ thousands of individuals. When working with such high volumes, challenges are inevitable, but our experience and dedication has helped us overcome every hurdle we have encountered. We want to ensure that every employee receives the compensation that they deserve but also that we are hiring the best workers for the organizations that we work alongside.”

At Lonestar Labor Management, they offer employees various benefits to help ease the burden of the current cost of living and improve their quality of life. Although working with thousands of individuals increases the number of challenges they face, Christopher and his team take pride in aiding communities.

When asked, “How has your definition of success changed over the years?” “Success has meant a lot of different things to me at different points in my professional journey. When I first started out in business, I mostly focused on maintaining a client base and generating enough revenue to stay afloat. However, as time went on it was more about helping out communities and putting my mark in the industry.”

Anyone interested in reading the full interview can do so on the Industry Elites website.

About Christopher Linton

Christopher Linton is the CEO of Lonestar Labor Management - a niche employment agency that strives to improve the quality of life for its employees. By providing a wide range of workforce solutions for companies across the United States, Christopher Linton ensures full-service staffing solutions within the food processing and manufacturing industry.

Media Contact
Contact Person: Christopher Linton
Email:Send Email
Country: United States
Website: lonestarlabormgt.com